MaaT Pharma SA (MAAT.PA)

9.1 €

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol MAAT.PA
Price 9.1 €
Beta 0.000
Volume Avg. 0.00M
Market Cap 89.989M
Shares () -
52 Week Range 7.4-13.55
1y Target Est -
DCF Unlevered MAAT.PA DCF ->
DCF Levered MAAT.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 42.80% Neutral
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Healthcare
Biotechnology
Paris

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.